Author:
Hernández-Terán Alejandra,Mejía-Nepomuceno Fidencio,Herrera María Teresa,Barreto Omar,García Emma,Castillejos Manuel,Boukadida Celia,Matias-Florentino Margarita,Rincón-Rubio Alma,Avila-Rios Santiago,Mújica-Sánchez Mario,Serna-Muñoz Ricardo,Becerril-Vargas Eduardo,Guadarrama-Pérez Cristobal,Ahumada-Topete Víctor Hugo,Rodríguez-Llamazares Sebastián,Martínez-Orozco José Arturo,Salas-Hernández Jorge,Pérez-Padilla Rogelio,Vázquez-Pérez Joel Armando
Abstract
AbstractThe COVID-19 outbreak has caused over three million deaths worldwide. Understanding the pathology of the disease and the factors that drive severe and fatal clinical outcomes is of special relevance. Studying the role of the respiratory microbiota in COVID-19 is especially important as the respiratory microbiota is known to interact with the host immune system, contributing to clinical outcomes in chronic and acute respiratory diseases. Here, we characterized the microbiota in the respiratory tract of patients with mild, severe, or fatal COVID-19, and compared it to healthy controls and patients with non-COVID-19-pneumonia. We comparatively studied the microbial composition, diversity, and microbiota structure between the study groups and correlated the results with clinical data. We found differences in the microbial composition for COVID-19 patients, healthy controls, and non-COVID-19 pneumonia controls. In particular, we detected a high number of potentially opportunistic pathogens associated with severe and fatal levels of the disease. Also, we found higher levels of dysbiosis in the respiratory microbiota of patients with COVID-19 compared to the healthy controls. In addition, we detected differences in diversity structure between the microbiota of patients with mild, severe, and fatal COVID-19, as well as the presence of specific bacteria that correlated with clinical variables associated with increased risk of mortality. In summary, our results demonstrate that increased dysbiosis of the respiratory tract microbiota in patients with COVID-19 along with a continuous loss of microbial complexity structure found in mild to fatal COVID-19 cases may potentially alter clinical outcomes in patients. Taken together, our findings identify the respiratory microbiota as a factor potentially associated with the severity of COVID-19.
Funder
Consejo Nacional de Ciencia y Tecnología
Publisher
Springer Science and Business Media LLC
Reference70 articles.
1. WHO. Weekly epidemiological update on COVID-19-11 May 2021. 11 May 32 (2021). https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---11-may-2021. Accessed 12 May 2021.
2. Baloch, S., Baloch, M. A., Zheng, T. & Pei, X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J. Exp. Med. 250, 271–278 (2020).
3. Sharma, R., Agarwal, M., Gupta, M., Somendra, S. & Saxena, S. K. Clinical characteristics and differential clinical diagnosis of novel coronavirus disease 2019 (COVID-19). in Coronavirus Disease 2019 (COVID-19): Epidemiology, Pathogenesis, Diagnosis, and Therapeutics (ed. Saxena, S. K.) 55–70 (Springer, 2020). doi:https://doi.org/10.1007/978-981-15-4814-7_6
4. Guan, W. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur. Respir. J. 55, 2000547 (2020).
5. Pijls, B. G. et al. Demographic risk factors for COVID-19 infection, severity, ICU admission and death: A meta-analysis of 59 studies. BMJ Open 11, 1–10 (2021).
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献